Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
gp100:209-217(210M) vaccine + IL-2 in advanced melanoma
NCT00005949Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Mar 2001
- Primary completion
- Mar 2006
- Modality
- Modified Peptides, Vaccines & Immunotherapeutics, Native Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of gp100:209-217(210M) in melanoma, sponsored by National Cancer Institute. Started Mar 2001; status: completed.
02
Drugs
gp100:209-217(210M)
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00005949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005949.